Stocks · News reference
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue
Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved positive adjusted EBITDA for the first time.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sonoma Pharmaceuticals Q1 EPS $(0.09) Up From $(0.76) YoY, Sales $6.406M Up From $4.015M YoY
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.09) per share. This is a 88.16 percent increase over losses of $(0.76) per share from the same period last year. The company reported $6.406 million
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance For Its Microdacyn Wound Irrigation Solution